Bioventus (BVS) CEO Robert Claypoole reports RSU vesting and tax share withholding

Rhea-AI Filing Summary

Bioventus Inc. President and CEO Robert E. Claypoole reported equity award activity involving the company’s Class A common stock. On January 9, 2026, 93,750 restricted stock units were converted into 93,750 shares of Class A common stock at an exercise price of $0. On the same date, 41,717 shares of Class A common stock were withheld at a price of $8.03 per share, typically reflecting shares withheld to cover taxes, leaving Claypoole with 116,997 shares of Class A common stock held directly after these transactions. Following the conversion, he also held 187,500 restricted stock units, each representing a contingent right to receive one share of Class A common stock. These RSUs vest in four equal installments on each of the first four anniversaries of January 10, 2024, subject to his continued service.

Insights

Equity compensation analyst

Routine RSU vesting and tax withholding leave CEO with higher net shareholdings.

The transactions show Robert E. Claypoole, President and CEO of Bioventus Inc., converting 93,750 restricted stock units into an equal number of Class A common shares at an exercise price of $0. This is standard for RSUs, which typically require no cash payment at vesting. After this conversion, his directly held Class A common stock position increased before tax-related withholding.

On the same January 9, 2026, 41,717 shares of Class A common stock were withheld at $8.03 per share under transaction code “F,” generally used for tax withholding. After these steps, Claypoole held 116,997 Class A shares directly, plus 187,500 RSUs outstanding. The RSUs vest in four equal annual installments starting on the January 10, 2024 anniversary, conditioned on his continued service, which ties his future compensation to ongoing tenure and share performance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Claypoole Robert E

(Last) (First) (Middle)

4721 EMPEROR BOULEVARD, SUITE 100

(Street)

DURHAM NC 27703

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Bioventus Inc. [ BVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	01/09/2026		M		93,750	A	$0	158,714	D
Class A Common Stock	01/09/2026		F		41,717	D	$8.03	116,997	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	01/09/2026		M			93,750	(2)	(2)	Class A Common Stock	93,750	$0	187,500	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.

2. The RSUs shall vest in four equal installments on each of the first four anniversaries of January 10, 2024, in each case subject to the Reporting Person continuing in service through the applicable vesting date.

Remarks:

	/s/ Anthony D'Adamio, Attorney-in-Fact	01/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the insider involved in this Bioventus (BVS) Form 4 filing?

The insider is Robert E. Claypoole, who serves as President and CEO and is also a director of Bioventus Inc.

What equity awards did Bioventus (BVS) CEO Robert Claypoole convert on January 9, 2026?

On January 9, 2026, Robert Claypoole converted 93,750 restricted stock units into 93,750 shares of Bioventus Class A common stock at an exercise price of $0 per share.

How many Bioventus (BVS) shares were withheld for taxes in this insider transaction?

The filing shows 41,717 shares of Class A common stock withheld at a price of $8.03 per share under transaction code “F,” which typically indicates shares withheld to cover tax obligations.

How many Bioventus (BVS) shares does the CEO hold after these transactions?

After the reported transactions on January 9, 2026, Robert Claypoole directly held 116,997 shares of Bioventus Class A common stock.

What is the remaining restricted stock unit position for the Bioventus (BVS) CEO?

Following the reported activity, Robert Claypoole beneficially owned 187,500 restricted stock units, each representing a contingent right to receive one share of Class A common stock.

What is the vesting schedule for the Bioventus (BVS) CEO’s restricted stock units?

The RSUs vest in four equal installments on each of the first four anniversaries of January 10, 2024, subject to Robert Claypoole continuing in service through each applicable vesting date.